Open AccessSodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
Author(s) -
Muhammad Shahzeb Khan,
Javed Butler
Publication year - 2019
Publication title -
cardiac failure review
Language(s) - English
Resource type - Journals
eISSN - 2057-7559
pISSN - 2057-7540
DOI - 10.15420/cfr.2019.06.r1
Subject(s) - heart failure , medicine , diabetes mellitus , cotransporter , type 2 diabetes , diabetic cardiomyopathy , canagliflozin , empagliflozin , dapagliflozin , cardiology , cardiomyopathy , endocrinology , pharmacology , sodium , chemistry , organic chemistry
Diabetes and heart failure (HF) are closely linked, with one causing a worse prognosis in the other. The majority of anti-hyperglycaemic agents primarily reduce risk of ischaemic microvascular events without targeting the mechanisms involved for diabetes cardiomyopathy and HF. Sodium–glucose cotransporter-2 (SGLT2) inhibitors have emerged as a novel class of glucose-lowering agents that have consistently reduced HF hospitalisations, unlike other agents. The authors discuss the current evidence and highlight possible future directions for the role of SGLT2 inhibitors in HF prevention.